Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

NCCN-IPI (Lymphoma)

The NCCN-IPI improves upon the original IPI by refining the scoring for Age and LDH, and emphasizing the importance of specific extranodal sites (Bone Marrow, CNS, Liver/GI, Lung).

Evidence-based context for fast calculator use

Purpose:
NCCN-IPI stratifies diffuse large B-cell lymphoma into four prognostic risk groups to guide rituximab-era chemoimmunotherapy treatment intensity.
Population:
patients with the specific hematologic diagnosis and disease phase described by the model
Factors:
Age, LDH Ratio, Involvement of Bone Marrow, CNS, Liver/GI, or Lung?, Ann Arbor Stage III or IV?, ECOG Performance Status ≥ 2?
Reference:
Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837-842.
HomeNCCN-IPI (Lymphoma)
Pin your most used calculators here by clicking the star in the dropdown.

NCCN-IPI (Lymphoma)

Clinical Context & Background

The NCCN-IPI improves upon the original IPI by refining the scoring for Age and LDH, and emphasizing the importance of specific extranodal sites (Bone Marrow, CNS, Liver/GI, Lung). It better discriminates between low and high risk groups in the Rituximab era.
Primary Source EvidenceZhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837-842.
Formula Logic
Sum of points for Age, LDH, Extranodal Sites, Ann Arbor Stage, and ECOG.

Reference Data

Risk GroupScore5-Year Overall Survival
Low Risk0 - 196%
Low-Intermediate2 - 382%
High-Intermediate4 - 564%
High Risk≥ 633%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use NCCN-IPI (Lymphoma) when nCCN-IPI stratifies diffuse large B-cell lymphoma into four prognostic risk groups to guide rituximab-era chemoimmunotherapy treatment intensity.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low Risk through High Risk.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm morphology, molecular/cytogenetic data, treatment timing, laboratory units, and the current disease-specific guideline before acting.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Hematology scores are diagnosis-, phase-, and treatment-specific and should not be transferred between diseases.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific hematologic diagnosis and disease phase described by the model

How to apply this result

For a representative case, verify Age, LDH Ratio, Involvement of Bone Marrow, CNS, Liver/GI, or Lung?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Hematology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

CLL-IPIMIPI (Mantle Cell Lymphoma)IPS (Hodgkin Lymphoma)

Frequently Asked Questions

When should NCCN-IPI (Lymphoma) be used?

Use it for patients with the specific hematologic diagnosis and disease phase described by the model when all required inputs and the intended clinical setting are confirmed.

Can NCCN-IPI (Lymphoma) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.